Retatrutide, a novel dual agonist of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) receptor , is demonstrating promising results in early human trials . Current research https://explorebookmarks.com/story21268572/retatrutide-emerging-studies-and-projected-clinical-roles